Malathi Kullappan

Dr. Malathi Kullappan

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2018 in Biotechnology and Genetic Engineering Reviews
Verified
Journal Article
Closed access
MKMalathi Kullappan
Malathi Kullappan
SRSudha Ramaiah
Sudha Ramaiah
Prolonged antibiotic therapy for the bacterial infections has resulted in high levels of antibiotic resistance. Initially, bacteria are susceptible to the antibiotics, but can gradually develop resistance. Treating such drug-resistant bacteria remains difficult or even impossible. Hence, there is a need to develop effective drugs against bacterial pathogens. The drug discovery process is time-consuming, expensive and laborious. The traditionally available drug discovery process initiates with the identification of target as well as the most promising drug molecule, followed by the optimization of this, in-vitro, in-vivo and in pre-clinical studies to decide whether the compound has the potential to be developed as a drug molecule. Drug discovery, drug development and commercialization are complicated processes. To overcome some of these problems, there are many computational tools available for new drug discovery, which could be cost effective and less time-consuming. In-silico approaches can reduce the number of potential compounds from hundreds of thousands to the tens of thousands which could be studied for drug discovery and this results in savings of time, money and human resources. Our review is on the various computational methods employed in new drug discovery processes.

24 February 2021 in Food Reviews International
Verified
Journal Article
Closed access
VVVishnu Priya Veeraraghavan
Vishnu Priya Veeraraghavan
SHSardar Hussain
Sardar Hussain
JBJanardhana Papayya Balakrishna
Janardhana Papayya Balakrishna
LDLavina Dhawale
Lavina Dhawale
MKMalathi Kullappan
Malathi Kullappan
Krishna Mohan SurapaneniKrishna Mohan Surapaneni
Krishna Mohan Surapaneni
Mushrooms and truffles have gained a lot of attention due to their aroma for culinary use and high nutritional content. Truffles, which are distributed in many African and European countries, have been successfully grown in recent times. Truffles are mycorrhizal fungi, which represent a symbiotic association of fungi Terfezia with the roots of Helianthemum species as host. Apart from being used as edibles, various biological uses of truffles have been reported which include antioxidant antiviral, antimicrobial, hepatoprotective, anti-mutagenic, and anti-inflammatory activities. In this review, we have summarized their classification with special emphasis on chemical constituents and biological activities of three desert truffles, viz. Terfezia boudieri, Terfezia claveryi, and Tirmania nivea. Strong antioxidant potential has been shown by these truffles along with antibacterial and antiviral effect in vitro and in animal studies (preclinical studies). These truffles have also been assessed for their anti-cancer and antidiabetic properties and were used as a folk medicine for their aphrodisiac powers which has been proven by various in vivo studies. The main drawback with the use of these truffles is that their bioactive components and properties have not been well studied. The detailed studies on these aspects would help in the use of these truffles for medicinal purposes in clinics.

6 May 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
JAJenifer Mallavarpu Ambrose
Jenifer Mallavarpu Ambrose
VVVishnu Priya Veeraraghavan
Vishnu Priya Veeraraghavan
MKMalathi Kullappan
Malathi Kullappan
PCPoongodi Chellapandiyan
Poongodi Chellapandiyan
Krishna Mohan SurapaneniKrishna Mohan Surapaneni
Krishna Mohan Surapaneni
VMVivek Anand Manivel
Vivek Anand Manivel
The current dynamics of the COVID-19 pandemic have become a serious concern with the emergence of a series of mutant variants of the SARS-CoV-2 virus. Unlike the previous strain, it is reported that the descendants are associated with increased risk of transmission yet causing less impact in terms of hospital admission, the severity of illness, or mortality. Moreover, the vaccine efficacy is also not believed to vary among the population depending on the variants of the virus and ethnicity. It has been determined that the mutations recorded in the spike gene and protein of the newly evolved viruses are specificallyresponsible for this transformation in the behavior of the virus and its disease condition. Hence, this study aimed to compare the immunogenic profiles of the spike protein from the latest variants of the SARS-CoV-2 virus concerning the probability of COVID-19 severity. Genome sequences of the latest SARS-CoV-2 variants were obtained from GISAID and NCBI repositories. The translated protein sequences were run against T-cell and B-cell epitope prediction tools. Subsequently, antigenicity, immunogenicity, allergenicity, toxicity, and conservancy of the identified epitopes were ascertained using various prediction servers. Only the non-allergic and non-toxic potential epitopes were matched for population relevance by using the Human Leucocyte Antigen population registry in IEDB. Finally, the selected epitopes were validated by docking and simulation studies. The evaluated immunological parameters would concurrently reveal the severity of COVID-19, determining the infection rate of the pathogen. Our immunoinformatics approach disclosed that spike protein of the five variants was capable of forming potential T and B-cell epitopes with varying immune responses. Although the Wuhan strain showed a high number of epitope/HLA combinations, relatively less antigenicity and higher immunogenicity results in poor neutralizing capacity, which could be associated with increased disease severity. Our data demonstrate that increased viral antigenicity with moderate to high immunogenicity, and several potential epitope/HLA combinations in England strain, the USA, India, and South Africa variants, could possess a high neutralizing ability. Therefore, our findings reinforce that the newly circulating variants of SARS-CoV-2 might be associated with more infectiousness and less severe disease condition despite their greater viremia, as reported in the recent COVID-19 cases, whichconsequently determine their increased epidemiological fitness.

8 March 2022 in Molecules
Verified
Journal Article
Open access
PDF file
JAJenifer Mallavarpu Ambrose
Jenifer Mallavarpu Ambrose
MKMalathi Kullappan
Malathi Kullappan
Shankargouda PatilShankargouda Patil
Shankargouda Patil
KAKhalid J. Alzahrani
Khalid J. Alzahrani
HBHamsa J. Banjer
Hamsa J. Banjer
Krishna Mohan SurapaneniKrishna Mohan Surapaneni
Krishna Mohan Surapaneni
The wild-type SARS-CoV-2 has continuously evolved into several variants with increased transmissibility and virulence. The Delta variant which was initially identified in India created a devastating impact throughout the country during the second wave. While the efficacy of the existing vaccines against the latest SARS-CoV-2 variants remains unclear, extensive research is being carried out to develop potential antiviral drugs through approaches like in silico screening and drug-repurposing. This study aimed to conduct the docking-based virtual screening of 50 potential phytochemical compounds against a Spike glycoprotein of the wild-type and the Delta SARS-CoV-2 variant. Subsequently, molecular docking was performed for the five best compounds, such as Lupeol, Betulin, Hypericin, Corilagin, and Geraniin, along with synthetic controls. From the results obtained, it was evident that Lupeol exhibited a remarkable binding affinity towards the wild-type Spike protein (−8.54 kcal/mol), while Betulin showed significant binding interactions with the mutated Spike protein (−8.83 kcal/mol), respectively. The binding energy values of the selected plant compounds were slightly higher than that of the controls. Key hydrogen bonding and hydrophobic interactions of the resulting complexes were visualized, which explained their greater binding affinity against the target proteins—the Delta S protein of SARS-CoV-2, in particular. The lower RMSD, the RMSF values of the complexes and the ligands, Rg, H-bonds, and the binding free energies of the complexes together revealed the stability of the complexes and significant binding affinities of the ligands towards the target proteins. Our study suggests that Lupeol and Betulin could be considered as potential ligands for SARS-CoV-2 spike antagonists. Further experimental validations might provide new insights for the possible antiviral therapeutic interventions of the identified lead compounds and their analogs against COVID-19 infection.

21 August 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MKMalathi Kullappan
Malathi Kullappan
BBBalakrishnan Anna Benedict
Balakrishnan Anna Benedict
ARAnusha Rajajagadeesan
Anusha Rajajagadeesan
PBPadmasini Baskaran
Padmasini Baskaran
NPNanthini Devi Periadurai
Nanthini Devi Periadurai
Krishna Mohan SurapaneniKrishna Mohan Surapaneni
Krishna Mohan Surapaneni
Zika virus is a member of the Flaviviridae family and genus Flavivirus, which has a phylogenetic relationship with spondweni virus. It spreads to humans through a mosquito bite. To identify potential inhibitors for the Zika virus with biosafety, we selected natural antiviral compounds isolated from plant sources and screened against NS3 helicase of the Zika virus. The enzymatic activity of the NS3 helicase is associated with the C‐terminal region and is concerned with RNA synthesis and genome replication. It serves as a crucial target for the Zika virus. We carried out molecular docking for the target NS3 helicase against the selected 25 phytochemicals using AutoDock Vina software. Among the 25 plant compounds, we identified NS3 helicase‐ellagic acid (‐9.9 kcal/mol), NS3 helicase‐hypericin (‐9.8 kcal/mol), and NS3 helicase‐pentagalloylglucose (‐9.5 kcal/mol) as the best binding affinity compounds based on their binding energies. To understand the stability of these complexes, molecular dynamic simulations were executed and the trajectory analysis exposed that the NS3 helicase‐ellagic acid complex possesses greater stability than the other two complexes such as NS3 helicase‐hypericin and NS3 helicase‐pentagalloylglucose. The ADMET property prediction of these compounds resulted in nontoxicity and noncarcinogenicity.

13 December 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
AKAndiyappan Kistan
Andiyappan Kistan
BBBalakrishnan Anna Benedict
Balakrishnan Anna Benedict
SVSundaramoorthy Vasanthan
Sundaramoorthy Vasanthan
APAlphonse PremKumar
Alphonse PremKumar
MKMalathi Kullappan
Malathi Kullappan
Krishna Mohan SurapaneniKrishna Mohan Surapaneni
Krishna Mohan Surapaneni
Emergence of antibiotic-resistant Mycobacterium tuberculosis (M. tuberculosis) restricts the availability of drugs for the treatment of tuberculosis, which leads to the increased morbidity and mortality of the disease worldwide. There are many intrinsic and extrinsic factors that have been reported for the resistance mechanism. To overcome such mechanisms, chemically synthesized benzaldehyde thiosemicarbazone derivatives were screened against M. tuberculosis to find potential inhibitor for tuberculosis. Such filtering process resulted in compound 13, compound 21, and compound 20 as the best binding energy compounds against DNA gyrase B, an important protein in the replication process. The ADMET prediction has shown the oral bioavailability of the novel compounds.